Session » SLE – Diagnosis, Manifestations, & Outcomes Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2401

A Novel Modeling Approach to Elucidate the Role of Autoantibodies in Complement Activation in SLE

10:30AM-12:30PM: Abstract Number: 2410

A Novel Treatment Response Measure for SLE Clinical Trials (TRM-SLE): Selection of Domains and Candidate Measures

10:30AM-12:30PM: Abstract Number: 2414

A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry

10:30AM-12:30PM: Abstract Number: 2409

Adherence to EULAR Recommendations and Sub Optimal Management of Systemic Lupus Erythematosus in a Network of Community-Based Rheumatology Practices in the United States

10:30AM-12:30PM: Abstract Number: 2390

Anti-Sm Antibody Titers Vary During SLE Disease Course

10:30AM-12:30PM: Abstract Number: 2411

Attainment of Complete Renal Response in Patients with Active Lupus Nephritis: A Multi-Center Cohort Study

10:30AM-12:30PM: Abstract Number: 2402

Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis

10:30AM-12:30PM: Abstract Number: 2387

Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus

10:30AM-12:30PM: Abstract Number: 2420

Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2375

Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?

10:30AM-12:30PM: Abstract Number: 2379

Causal Proteomics-Assisted Machine Learning Model Enhances Flare Risk Prediction in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2374

Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia

10:30AM-12:30PM: Abstract Number: 2380

Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort

10:30AM-12:30PM: Abstract Number: 2415

Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network

10:30AM-12:30PM: Abstract Number: 2405

Chat-GPT Performance in Diagnosis of Rheumatological Diseases: A Comparison with Specialist’s Opinion

10:30AM-12:30PM: Abstract Number: 2389

Choroidal Thickness in Active Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 2419

Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data

10:30AM-12:30PM: Abstract Number: 2392

Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study

10:30AM-12:30PM: Abstract Number: 2381

Clinical Characteristics, Readmission Rates, and Outcomes in Lupus Patients with and Without Nephritic Involvement: Analysis from a National Database

10:30AM-12:30PM: Abstract Number: 2407

Clinical Utility of Repeat Renal Biopsies in Lupus Nephritis: The NIH Chronicity Index at First Biopsy Predicts Future End Stage Renal Disease in a Large South Asian Cohort of SLE

10:30AM-12:30PM: Abstract Number: 2393

Demographic Differences in Trends of Systemic Lupus Erythematosus In-hospital Patient Outcomes

10:30AM-12:30PM: Abstract Number: 2417

Frequency and Associated Factors of Herpes Zoster Infection in Systemic Lupus Erythematosus Patients from Latin-America

10:30AM-12:30PM: Abstract Number: 2403

Health-related Quality of Life in Women with Systemic Lupus Erythematosus with Permanent Skin Damage and Its Association with Self-esteem and Symptoms of Depression and Anxiety – a Cross-sectional Study

10:30AM-12:30PM: Abstract Number: 2418

Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)

10:30AM-12:30PM: Abstract Number: 2391

Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise

10:30AM-12:30PM: Abstract Number: 2377

Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY

10:30AM-12:30PM: Abstract Number: 2408

Impact of Pain and Fatigue on Quality of Life Among Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2372

Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2397

Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients

10:30AM-12:30PM: Abstract Number: 2385

Increased Type I Interferon Inducible Genes Expression in the Peripheral Blood of Patients Presenting Cutaneous Lupus Erythematosus Manifestations

10:30AM-12:30PM: Abstract Number: 2378

Is Urinary Protein-creatinine Relation Reliable for Diagnosis or Follow up of Lupus Nephritis?

10:30AM-12:30PM: Abstract Number: 2386

Landscape of Immune Cells and Autoimmunity in Systemic Lupus Erythematosus Patients with Obesity

10:30AM-12:30PM: Abstract Number: 2404

Nailfold Dermoscopy: A Valuable Tool for Differentiating Dermatomyositis from Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2399

Nationwide Analysis of Endovascular Thrombectomy in Ischemic Stroke Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mortality and Healthcare Utilization

10:30AM-12:30PM: Abstract Number: 2406

Neuropsychiatric Manifestations in Indian SLE Inception Cohort for Research: Prevalence, Predictors and Outcomes

10:30AM-12:30PM: Abstract Number: 2383

Outcomes of Systemic Lupus Erythematosus Hospitalizations: Insights from a Multinational Tertiary Center Experience

10:30AM-12:30PM: Abstract Number: 2384

Performance and Concordance of Two Different Methods of Detecting the Commonest Autoantibodies in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2394

Perioperative Stress Dose vs Therapeutic Dose Comparison: One-Month Postoperative Outcomes in Moderate and Major Surgeries for Systemic Lupus Erythematous and Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2400

Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts

10:30AM-12:30PM: Abstract Number: 2396

PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE

10:30AM-12:30PM: Abstract Number: 2388

Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2370

Redefining Clinical Trial Inclusion Criteria Using Quality of Life in Cutaneous Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2376

Systemic Lupus Erythematosus Patients Exhibit Dynamic Changes in Disease-Associated Transcripts Following Total Knee or Total Hip Arthroplasty

10:30AM-12:30PM: Abstract Number: 2373

The Construction and Validation of Sub-phenotype-specific Genetic Risk Scores in Systemic Lupus Erythematosus: A Novel Approach Using Large-scale Biobank Data

10:30AM-12:30PM: Abstract Number: 2416

The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort

10:30AM-12:30PM: Abstract Number: 2413

The Natural History of SLE Has Changed Since the 1970s

10:30AM-12:30PM: Abstract Number: 2398

The Relationship Between First-Trimester Maternal Serum 25-Hydroxyvitamin D and Maternal/Fetal Outcomes in Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2371

The Role of Intracytoplasmic Toll- Like Receptors (TLR) and MyD88 in B Cell Subsets as Renal Response Predictors in Patients with Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 2382

Utility of Urinary Biomarkers to Predict Long-term Renal Outcomes in Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 2395

Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)

10:30AM-12:30PM: Abstract Number: 2412

Validation of Proposals for Definitions of Moderate and Severe Disease Activity in Systemic Lupus Erythematosus, Based on Data Gathered from the RELESSER-PROS Register Database

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].